Notices. Extension of comment period

374 words·~2 min read·/register/2020/06/19/2020-13278

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

BILLING CODE 6712-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention [Docket No. CDC-2020-0046; NIOSH-233-C] Hazardous Drugs: Draft NIOSH List of Hazardous Drugs in Healthcare Settings, 2020; Procedures; and Risk Management Information; Extension of Comment Period AGENCY: Centers for Disease Control and Prevention, HHS. ACTION: Extension of comment period. SUMMARY: On May 1, 2020, the National Institute for Occupational Safety and Health (NIOSH), within the Center for Disease Control and Prevention (CDC), opened a docket to obtain public input on the following draft documents:

(1)*NIOSH Procedures for Developing the NIOSH List of Hazardous Drugs in Healthcare Settings (Procedures);*

(2)*NIOSH List of Hazardous Drugs in Healthcare Settings, 2020* *(List)* , and

(3)*Managing Hazardous Drug Exposures: Information for Healthcare Settings.* Comments were to be received by June 30, 2020. NIOSH is extending the comment period to close on July 30, 2020, to allow stakeholders and other interested parties additional time to respond. DATES: The comment period for the document published on May 1, 2020 (85 FR 25439), is extended. Comments must be received by July 30, 2020. ADDRESSES: You may submit written comments, identified by docket numbers CDC-2020-0046 and NIOSH-233-C, by either of the following two methods: • *Federal eRulemaking Portal:* *http://www.regulations.gov.* Follow the instructions for submitting comments. • *Mail:* National Institute for Occupational Safety and Health, NIOSH Docket Office, 1090 Tusculum Avenue, MS C-34, Cincinnati, Ohio 45226-1998. *Instructions:* All information received in response to this notice must include the agency name and docket number [CDC-2020-0046; NIOSH-233-C]. All relevant comments received will be posted without change to *http://www.regulations.gov,* including any personal information provided. FOR FURTHER INFORMATION CONTACT: Barbara MacKenzie, NIOSH, Robert A. Taft Laboratories, 1090 Tusculum Avenue, MS-C26, Cincinnati, OH 45226; phone:

(513)533-8132 (not a toll-free number); email: *bmackenzie@cdc.gov.* SUPPLEMENTARY INFORMATION: NIOSH published a notice and request for comment in the **Federal Register** on May 1, 2020 (85 FR 25439) regarding the development of the *NIOSH List of Hazardous Drugs in Healthcare Settings* and related risk management information for healthcare settings. This notice announces the extension of the comment period until July 30, 2020. John J. Howard, Director, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention. [FR Doc. 2020-13278 Filed 6-18-20; 8:45 am]